We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Denator Expands Asian Distributor Network

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Denator Expands Asian Distributor Network"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Denator AB has announced that the company has appointed ASPEC Technologies Limited and D.I Biotech Ltd. as new distributors of its Stabilizor™ system in selected Asian markets.

Under the terms of the agreements, ASPEC and DI Biotech will market, sell and provide support for Denator’s range of sample preservation products. ASPEC will cover the geographical markets of China, Hong Kong, Taiwan and Macau and DI Biotech will cover the Korean market.

Denator’s proprietary heat-stabilization technology is an additive-free preservation technology for biological samples which stops degradation and changes immediately and permanently. This ensures a stable sample from the moment of excision until the point of analysis which increases the accuracy and quality of analytical results.

Karsten Fjärstedt, VP Global Marketing and Sales at Denator, comments: “We are very happy to have such well-respected distributors as ASPEC and DI Biotech representing our products. This expansion of our distributor network will strengthen our presence in the important Asian market. During the spring Denator will, together with our new partners, conduct a sales tour and attend selected conferences in the region to drive the adoption of our heat-stabilization technology.”

By using heat-stabilization, scientists have been able to drastically improve the consistency of sample quality and discover new, biologically-relevant information without needing to use additives like inhibitors.

This is of particular significance to research areas such as neuroscience, oncology and proteomic research, where short-lived molecules and potential biomarkers need to be confidently identified in order to understand disease mechanisms and identify potential drug targets or disease markers. Users typically include pharmaceutical companies, academic labs, clinical research facilities and biobanks.